Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Livdelzi will launch at a list price of $12,606 for a 30-day treatment cycle, a little higher than the $11,500 per month set by Ipsen for Iqirvo, which is a dual PPAR alpha/delta agonist.

Tempest Therapeutics (NASDAQ:TPST – Get Free Report) is anticipated to issue its quarterly earnings data before the market ...

Iron-dependent ferroptosis, a non-apoptotic cell death mechanism, is gaining attention for its role in immune suppression.

So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

We also show PPARG-metabolite interactions (brown-yellow edges), and metabolite-protein interactions (light gray edges). Peroxisome proliferator-activated receptor alpha (PPARA), peroxisome ...

Objective Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor expressed in tissues with high oxidative activity that plays a central role in metabolism. In this work, we ...

and peroxisome proliferator-activated receptors (PPARs). Similarly, MALAT1 has been shown to exacerbate liver fibrosis by modulating inflammatory pathways via nuclear factor-kappa B (NF-κB ...

After hours: March 21 at 7:45:35 PM EDT Loading Chart for TPST ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.